Monaco Asset Management SAM Makes New $526,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Monaco Asset Management SAM acquired a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 240,000 shares of the company's stock, valued at approximately $526,000. Monaco Asset Management SAM owned approximately 0.34% of Ventyx Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Connor Clark & Lunn Investment Management Ltd. lifted its position in Ventyx Biosciences by 88.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company's stock valued at $1,909,000 after acquiring an additional 409,357 shares in the last quarter. Palumbo Wealth Management LLC lifted its position in Ventyx Biosciences by 97.1% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock valued at $52,000 after acquiring an additional 11,792 shares in the last quarter. Rhumbline Advisers lifted its position in Ventyx Biosciences by 44.4% in the 4th quarter. Rhumbline Advisers now owns 132,825 shares of the company's stock valued at $291,000 after acquiring an additional 40,813 shares in the last quarter. Catalina Capital Group LLC bought a new position in Ventyx Biosciences in the 4th quarter valued at approximately $25,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Ventyx Biosciences by 2.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company's stock valued at $2,196,000 after buying an additional 20,236 shares during the period. 97.88% of the stock is owned by institutional investors.

Remove Ads

Insider Transactions at Ventyx Biosciences

In other Ventyx Biosciences news, Director Sheila Gujrathi purchased 130,000 shares of the business's stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the purchase, the director now owns 130,000 shares of the company's stock, valued at approximately $300,300. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John Nuss sold 13,161 shares of the stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total value of $29,743.86. Following the completion of the sale, the insider now owns 485,701 shares of the company's stock, valued at $1,097,684.26. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. 18.18% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "neutral" rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX traded down $0.04 during midday trading on Tuesday, hitting $1.37. The company had a trading volume of 775,887 shares, compared to its average volume of 1,269,487. The company has a market cap of $97.45 million, a price-to-earnings ratio of -0.58 and a beta of 0.58. Ventyx Biosciences, Inc. has a 12-month low of $1.34 and a 12-month high of $8.12. The company has a fifty day moving average of $1.78 and a two-hundred day moving average of $2.10.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.13. Research analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.